Company Description
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases.
The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases.
It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 2012 |
| IPO Date | Sep 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 187 |
| CEO | Daniel de Boer |
Contact Details
Address: Zernikedreef 9 Leiden, 2333 CK Netherlands | |
| Phone | 31 88 166 7000 |
| Website | proqr.com |
Stock Details
| Ticker Symbol | PRQR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612940 |
| CUSIP Number | N71542109 |
| ISIN Number | NL0010872495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Anton de Boer | Founder, Chief Executive Officer and Executive Director |
| Dr. Gerard Platenburg Ph.D. | Co-Founder, Chief Scientific Officer and Executive Director |
| Dennis Hom | Chief Financial Officer |
| Sheila Sponselee | Chief People and Operations Officer |
| Sarah Cue Kiely | Vice President of Investor Relations and Corporate Communications |
| Dr. Cristina Lopez Lopez M.D., Ph.D. | Chief Medical Officer |
| Sandra van der Kolk | Junior Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2026 | 6-K | Report of foreign issuer |
| Mar 12, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 12, 2026 | 6-K | Report of foreign issuer |
| Feb 9, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | SCHEDULE 13D/A | Filing |
| Jan 20, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Nov 6, 2025 | 6-K | Report of foreign issuer |
| Nov 3, 2025 | 6-K | Report of foreign issuer |
| Oct 20, 2025 | 6-K | Report of foreign issuer |